<DOC>
	<DOCNO>NCT01602289</DOCNO>
	<brief_summary>The purpose study assess safety tolerability LY2875358 Japanese participant cancer advance and/or may spread another part body .</brief_summary>
	<brief_title>A Study LY2875358 Japanese Participants With Advanced Cancer</brief_title>
	<detailed_description>This study 3 part . Participants may enroll one part . Part A - Participants receive LY2875358 . Part B1 - Participants non-small cell lung cancer ( NSCLC ) receive LY2875358 erlotinib . Part B2 - Participants NSCLC receive LY2875358 gefitinib . Parts B1 B2 add per protocol amendment January , 2013 .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Part A : Have histological cytological evidence malignancy ( solid tumor lymphoma ) advance and/or metastatic . The participant must , judgment investigator , appropriate candidate experimental therapy available standard therapy use Part B1 : Have histologic cytologic diagnosis advance NSCLC , Stage IV per 7th edition American Joint Committee Cancer ( AJCC ) Staging Criteria NSCLC . The participant must effective therapeutic option eligible erlotinib therapy per Japanese package insert opinion investigator Part B2 : Have histologic cytologic diagnosis advance NSCLC epidermal growth factor receptor ( EGFR ) activate mutation , Stage IV per 7th edition AJCC Staging Criteria NSCLC . The participant must effective therapeutic option eligible gefitinib therapy per Japanese package insert opinion investigator Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Revised Response Criteria Malignant Lymphoma Have adequate hematologic , hepatic renal function Have performance status ≤2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous cancer therapy , agent receive regulatory approval indication , least 21 day 5 half life prior study enrollment , whichever short , recover acute effect therapy ( treatmentrelated toxicity resolve baseline ≤ Grade 1 ) . Participants must discontinue mitomycinC nitrosourea therapy least 42 day Males female reproductive potential : Must agree use medically approve contraceptive precaution study 4 month follow last dose study drug judgment investigator , safe participant become pregnant Females child bear potential : Have negative urine pregnancy test ≤7 day first dose study drug must also breastfeed . If female stop breastfeeding enter study , female must stop breastfeeding day first study drug administration 4 month last dose Have estimate life expectancy , judgment investigator , permit participant complete 8 week treatment Have serious preexist medical condition Part A : Have symptomatic central nervous system malignancy metastasis Part B : Have brain metastasis symptomatic require ongoing treatment steroid radiation therapy Have current acute chronic leukemia ( participant adult Tcell leukemia/lymphoma eligible ) Have active fungal , bacterial , and/or know viral infection Have second primary malignancy judgment investigator sponsor may affect interpretation result Have history New York Heart Association ( NYHA ) class ≥3 , unstable angina , myocardial infarction 6 month prior study drug administration Have QTc interval &gt; 470 millisecond ( msec ) screen electrocardiogram Have receive liver transplant , liver cirrhosis ChildPugh Stage B C Participants active alcohol abuse , determine treat investigator Previous treatment extracellular domain mesenchymalepithelial transition factor ( cMET ) target experimental therapeutic ( example , XL184 , ARQ197 , onartuzumab ) Have history radiation therapy involve 25 % bone marrow . Previous radiation therapy allow limited must include whole pelvis radiation Part B : The participant actively receive warfarin therapy time enrollment Part B : Concomitant treatment cytochrome P450 ( CYP ) 3A4 modulators . The participant must receive treatment modulators within 14 day Cycle 1 Day 1 Part B : Have evidence clinically active interstitial lung disease ( ILD ) . Asymptomatic participant chronic , stable , radiographic change eligible Part B : Have preexist interstitial lung disease risk evidence compute tomography ( CT ) scan/Xray baseline ; disease acute lung injury , idiopathic pulmonary fibrosis , pneumonitis , pneumoconiosis evident xray ; disease radiation pneumonia druginduced pneumonia , require treatment corticosteroid Part B : Have previously intolerant therapy erlotinib gefitinib</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>